Literature DB >> 16456863

An open trial of paroxetine for the "offensive subtype" of taijin kyofusho and social anxiety disorder.

Toshihiko Nagata1, Irene van Vliet, Hisashi Yamada, Kouhei Kataoka, Toshiya Iketani, Nobuo Kiriike.   

Abstract

The taijin kyofusho (TKS) offensive subtype is thought to be a culture-bound syndrome similar to social anxiety disorder (SAD). In Western countries, such patients would be diagnosed as having delusional disorder, somatic subtype, or body dysmorphic disorder. Recently, open trials for the TKS offensive subtype and a randomized controlled trial for body dysmorphic disorder demonstrated that selective serotonin reuptake inhibitors (SSRIs) might be as effective in TKS as in SAD. This study investigated the efficacy of the SSRI paroxetine in patients with the TKS offensive subtype, both on anxiety and fears, as well as insight. This study was a 12-week open trial using paroxetine in 22 patients with TKS. Subjects were diagnosed based on the original diagnostic criteria for the TKS offensive subtype. Insight regarding TKS symptoms was assessed by the 11th supplement subscale "Insight into obsessions and compulsions" of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The Liebowitz Social Anxiety Scale (LSAS), the Beck Depression Inventory (BDI), the State-Trait Anxiety Inventory (STAI), Rosenberg's Self-Esteem Scale, and the Interpersonal Distrust subscale of the Eating Disorder Inventory were also administered. Offensive anxiety was assessed by the original TKS offensive anxiety subscale (0-3 points). The primary efficacy variable was the Clinical Global Impression scale (CGI) global improvement item. Nineteen patients completed the study. Forty-seven percent (9/19) were responders to the drug treatment (scoring 2 or less on the CGI). Last observation carried forward (LOCF) analysis (N=22) demonstrated a statistically significant reduction in LSAS total score and offensive anxiety in TKS, and the insight scale score of the Y-BOCS also significantly improved. Interpersonal distrust showed a trend toward improvement.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456863     DOI: 10.1002/da.20153

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  7 in total

Review 1.  Cultural aspects in social anxiety and social anxiety disorder.

Authors:  Stefan G Hofmann; M A Anu Asnaani; Devon E Hinton
Journal:  Depress Anxiety       Date:  2010-12       Impact factor: 6.505

Review 2.  Recent Insight Into the Subtypes of Social Anxiety Disorder.

Authors:  Catherine D'Avanzato; Kristy L Dalrymple
Journal:  Curr Psychiatry Rep       Date:  2016-05       Impact factor: 5.285

3.  Cross-cultural study of conviction subtype Taijin Kyofu: proposal and reliability of Nagoya-Osaka diagnostic criteria for social anxiety disorder.

Authors:  Yoshihiro Kinoshita; Junwen Chen; Ronald M Rapee; Susan Bögels; Franklin R Schneier; Yujuan Choy; Jung-Hye Kwon; Xinghua Liu; Elisabeth Schramm; Denise A Chavira; Yumi Nakano; Norio Watanabe; Tetsuji Ietzugu; Sei Ogawa; Paul Emmelkamp; Jianxue Zhang; David Kingdon; Toshihiko Nagata; Toshi A Furukawa
Journal:  J Nerv Ment Dis       Date:  2008-04       Impact factor: 2.254

Review 4.  Culture and the anxiety disorders: recommendations for DSM-V.

Authors:  Roberto Lewis-Fernández; Devon E Hinton; Amaro J Laria; Elissa H Patterson; Stefan G Hofmann; Michelle G Craske; Dan J Stein; Anu Asnaani; Betty Liao
Journal:  Depress Anxiety       Date:  2010-02       Impact factor: 6.505

5.  Psychotic symptoms in social anxiety disorder patients: report of three cases.

Authors:  André B Veras; Júlia S do-Nascimento; Regis L Rodrigues; Ana Carolina A Guimarães; Antonio E Nardi
Journal:  Int Arch Med       Date:  2011-04-10

6.  Taijin kyofusho and social anxiety and their clinical relevance in indonesia and Switzerland.

Authors:  N Vriends; M C Pfaltz; P Novianti; J Hadiyono
Journal:  Front Psychol       Date:  2013-02-04

7.  Prevalence of mental disorders based on general population surveys.

Authors:  Harald Baumeister; Martin Härter
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-05-21       Impact factor: 4.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.